Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brilaroxazine
- Development stage
- Phase 3
- Lead developer
- Reviva Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Brilaroxazine is a novel, investigational third-generation antipsychotic and serotonin-dopamine system modulator developed by Reviva Pharmaceuticals. It acts as a partial agonist at dopamine D2, D3, D4 and serotonin 1A and 2A receptors, while antagonizing serotonin 6 and 7 receptors. This unique receptor profile distinguishes it from other antipsychotics and underpins its broad-spectrum efficacy in neuropsychiatric disorders. Brilaroxazine is being developed primarily for schizophrenia (Phase III), with additional development for schizoaffective disorder (Phase II), bipolar disorder, major depressive disorder, ADHD, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and psoriasis. The drug has demonstrated robust efficacy across all major symptom domains of schizophrenia with a favorable safety profile in clinical trials[1][2][4][5][8].
- Other names
- brilaroxazine lipogelBRILAROXAZINE [INN]RP 5000RP5000RP-5000
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR6 (5-hydroxytryptamine receptor 6)HTR7 (5-hydroxytryptamine receptor 7)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on brilaroxazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brilaroxazine.